Zacks: Prima BioMed Ltd. (PBMD) Receives Average Rating of “Strong Buy” from Analysts
Shares of Prima BioMed Ltd. (NASDAQ:PBMD) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price target of $5.00 for the company, according to Zacks. Zacks has also given Prima BioMed an industry rank of 111 out of 265 based on the ratings given to related companies.
PBMD has been the topic of a number of research reports. FBR & Co set a $6.00 price target on Prima BioMed and gave the stock a “buy” rating in a research note on Thursday, September 8th. Zacks Investment Research downgraded Prima BioMed from a “buy” rating to a “hold” rating in a research note on Saturday, June 18th. Maxim Group reaffirmed a “buy” rating on shares of Prima BioMed in a research note on Wednesday, June 22nd. Finally, HC Wainwright reissued a “buy” rating on shares of Prima BioMed in a research note on Wednesday, June 22nd.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/zacks-prima-biomed-ltd-pbmd-receives-average-rating-of-strong-buy-from-analysts.html
Shares of Prima BioMed (NASDAQ:PBMD) traded down 0.10% on Friday, hitting $0.87. The stock had a trading volume of 40,080 shares. Prima BioMed has a 52 week low of $0.72 and a 52 week high of $1.54. The company has a 50-day moving average of $0.88 and a 200 day moving average of $0.95. The company’s market capitalization is $59.79 million.
Prima BioMed Company Profile
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.